drugset
drugset / Trial / NCT04261712

A Study to Evaluate the Long-Term Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Advance)

NCT04261712 ↗

Phase 2 Active not recruiting 43 enrolled Crinetics Pharmaceuticals Inc.
NaSingle-groupOpen-labelTreatment

Summary

A phase 2, open label, long-term extension study designed to evaluate the safety and efficacy of paltusotine (formerly CRN00808; an oral selective nonpeptide somatostatin receptor type 2 biased agonist) in subjects with acromegaly.

Timeline

Start
2020-01-29
Primary completion
2028-03-31
Completion
2028-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Paltusotine Small molecule — Oral

Indications

acromegaly